Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
30/03/2026 14:47
March 30 (Reuters) - Aquestive Therapeutics Inc AQST.O: AQUESTIVE THERAPEUTICS ANNOUNCES COMPLETION OF TYPE A MEETING WITH FDA FOR ANAPHYLM™ (DIBUTEPINEPHRINE) SUBLINGUAL FILM AQUESTIVE THERAPEUTICS INC - REAFFIRMS GUIDANCE TO RESUBMIT ANAPHYLM NDA IN Q3 2026 AQUESTIVE THERAPEUTICS INC - RECEIVES CLARIFYING FEEDBACK FROM FDA ON PHARMACOKINETIC (PK) & HUMAN FACTOR (HF) STUDY DESIGNS AQUESTIVE THERAPEUTICS INC - CONTINUES TO ADVANCE REGULATORY SUBMISSIONS FOR ANAPHYLM IN CANADA AND THE EUROPEAN UNION Source text: ID:nGNX9NFVXy Further company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma